Leptin-mediated suppression of lipoprotein lipase cleavage enhances lipid uptake and facilitates lymph node metastasis in gastric cancer

Abstract

Background: Lymph node metastasis (LNM) is the primary mode of metastasis in gastric cancer (GC). However, the precise mechanisms underlying this process remain elusive. Tumor cells necessitate lipid metabolic reprogramming to facilitate metastasis, yet the role of lipoprotein lipase (LPL), a pivotal enzyme involved in exogenous lipid uptake, remains uncertain in tumor metastasis. Therefore, the aim of this study was to investigate the presence of lipid metabolic reprogramming during LNM of GC as well as the role of LPL in this process.

Methods: Intracellular lipid levels were quantified using oil red O staining, BODIPY 493/503 staining, and flow cytometry. Lipidomics analysis was employed to identify alterations in intracellular lipid composition following LPL knockdown. Protein expression levels were assessed through immunohistochemistry, Western blotting, and enzyme-linked immunosorbent assays. The mouse popliteal LNM model was utilized to investigate differences in LNM. Immunoprecipitation and mass spectrometry were employed to examine protein associations. In vitro phosphorylation assays and Phos-tag sodium dodecyl-sulfate polyacrylamide gel electrophoresis assays were conducted to detect angiopoietin-like protein 4 (ANGPTL4) phosphorylation.

Results: We identified that an elevated intracellular lipid level represents a crucial characteristic of node-positive (N+) GC and further demonstrated that a high-fat diet can expedite LNM. LPL was found to be significantly overexpressed in N+ GC tissues and shown to facilitate LNM by mediating dietary lipid uptake within GC cells. Leptin, an obesity-related hormone, intercepted the effect exerted by ANGPTL4/Furin on LPL cleavage. Circulating leptin binding to the leptin receptor could induce the activation of inositol-requiring enzyme-1 (IRE1) kinase, leading to the phosphorylation of ANGPTL4 at the serine 30 residue and subsequently reducing its binding affinity with LPL. Moreover, our research revealed that LPL disrupted lipid homeostasis by elevating intracellular levels of arachidonic acid, which then triggered the cyclooxygenase-2/prostaglandin E2 (PGE2) pathway, thereby promoting tumor lymphangiogenesis.

Conclusions: Leptin-induced phosphorylation of ANGPTL4 facilitates LPL-mediated lipid uptake and consequently stimulates the production of PGE2, ultimately facilitating LNM in GC.

Keywords

angiopoietin-like protein 4 / leptin / lipoprotein lipase / lymph node metastasis / prostaglandin E2

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.

[2] Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022; 2(1): 1–9.

[3] Feng R, Su Q, Huang X, Basnet T, Xu X, Ye W. Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? Cancer Commun (Lond). 2023; 43(1): 75–86.

[4] Wang Z, Han W, Xue F, Zhao Y, Wu P, Chen Y, et al. Nationwide gastric cancer prevention in China, 2021-2035: a decision analysis on effect, affordability and cost-effectiveness optimisation. Gut. 2022; 71(12): 2391–2400.

[5] Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021; 24(1): 1–21.

[6] Reticker-Flynn NE, Zhang W, Belk JA, Basto PA, Escalante NK, Pilarowski GOW, et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell. 2022; 185(11): 1924–1942.e23.

[7] Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021; 71(3): 264–279.

[8] Ricci AD, Rizzo A, Brandi G. DNA damage response alterations in gastric cancer: knocking down a new wall. Future Oncol. 2021; 17(8): 865–868.

[9] Ricci AD, Rizzo A, Rojas Llimpe FL, Di Fabio F, De Biase D, Rihawi K. Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift? Cancers (Basel). 2021; 13(7): 1664.

[10] Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, et al. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Crit Rev Oncol Hematol. 2022; 170: 103596.

[11] Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021; 218(1): e20201606.

[12] Martin-Perez M, Urdiroz-Urricelqui U. Bigas C, Benitah SA. The role of lipids in cancer progression and metastasis. Cell Metab. 2022; 34(11): 1675–1699.

[13] Dai W, Xiang W, Han L, Yuan Z, Wang R, Ma Y, et al. PTPRO represses colorectal cancer tumorigenesis and progression by reprogramming fatty acid metabolism. Cancer Commun (Lond). 2022; 42(9): 848–867.

[14] Lee CK, Jeong SH, Jang C, Bae H, Kim YH, Park I, et al. Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science. 2019; 363(6427): 644–649.

[15] Majima M, Hosono K, Ito Y, Amano H. Biologically active lipids in the regulation of lymphangiogenesis in disease states. Pharmacol Ther. 2022; 232: 108011.

[16] Ogawa F, Amano H, Eshima K, Ito Y, Matsui Y, Hosono K, et al. Prostanoid induces premetastatic niche in regional lymph nodes. J Clin Invest. 2014; 124(11): 4882–4894.

[17] Xiao J, Shen K, Liu K, Wang Y, Fan H, Cheng Q, et al. Obesity promotes lipid accumulation in lymph node metastasis of gastric cancer: a retrospective case–control study. Lipids Health Dis. 2022; 21(1): 123.

[18] Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013; 52(4): 585–589.

[19] Corn KC, Windham MA, Rafat M. Lipids in the tumor microenvironment: From cancer progression to treatment. Prog Lipid Res. 2020; 80: 101055.

[20] Mahmud I, Tian G, Wang J, Hutchinson TE, Kim BJ, Awasthee N, et al. DAXX drives de novo lipogenesis and contributes to tumorigenesis. Nat Commun. 2023; 14(1): 1927.

[21] Li S, Wu T, Lu YX, Wang JX, Yu FH, Yang MZ, et al. Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis. Redox Biol. 2020; 36: 101596.

[22] Jiang M, Wu N, Xu B, Chu Y, Li X, Su S, et al. Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis. Theranostics. 2019; 9(18): 5359–5373.

[23] Kitayama J, Hatano K, Kaisaki S, Suzuki H, Fujii S, Nagawa H. Hyperlipidaemia is positively correlated with lymph node metastasis in men with early gastric cancer. Br J Surg. 2004; 91(2): 191–198.

[24] Kim H, Song Z, Zhang R, Davies BSJ, Zhang K. A hepatokine derived from the ER protein CREBH promotes triglyceride metabolism by stimulating lipoprotein lipase activity. Sci Signal. 2023; 16(768): eadd6702.

[25] Olivecrona G. Role of lipoprotein lipase in lipid metabolism. Curr Opin Lipidol. 2016; 27(3): 233–241.

[26] Lupien LE, Bloch K, Dehairs J, Traphagen NA, Feng WW, Davis WL, et al. Endocytosis of very low-density lipoproteins: an unexpected mechanism for lipid acquisition by breast cancer cells. J Lipid Res. 2020; 61(2): 205–218.

[27] Wu Z, Ma H, Wang L, Song X, Zhang J, Liu W, et al. Tumor suppressor ZHX2 inhibits NAFLD-HCC progression via blocking LPL-mediated lipid uptake. Cell Death Differ. 2020; 27(5): 1693–1708.

[28] Kuemmerle NB, Rysman E, Lombardo PS, Flanagan AJ, Lipe BC, Wells WA, et al. Lipoprotein lipase links dietary fat to solid tumor cell proliferation. Mol Cancer Ther. 2011; 10(3): 427–436.

[29] Wu SA, Kersten S, Qi L. Lipoprotein Lipase and Its Regulators: An Unfolding Story. Trends Endocrinol Metab. 2021; 32(1): 48–61.

[30] Xiao J, Lin L, Luo D, Shi L, Chen W, Fan H, et al. Long noncoding RNA TRPM2-AS acts as a microRNA sponge of miR-612 to promote gastric cancer progression and radioresistance. Oncogenesis. 2020; 9(3): 29.

[31] Aoki T, Kinoshita J, Munesue S, Hamabe-Horiike T. Yamaguchi T, Nakamura Y, et al. Hypoxia-Induced CD36 Expression in Gastric Cancer Cells Promotes Peritoneal Metastasis via Fatty Acid Uptake. Ann Surg Oncol. 2023; 30(5): 3125–3136.

[32] Cheng Q, Liu K, Xiao J, Shen K, Wang Y, Zhou X, et al. SEC23A confers ER stress resistance in gastric cancer by forming the ER stress-SEC23A-autophagy negative feedback loop. J Exp Clin Cancer Res. 2023; 42(1): 232.

[33] Ma X, Wang G, Fan H, Li Z, Chen W, Xiao J, et al. Long noncoding RNA FAM225A promotes the malignant progression of gastric cancer through the miR-326/PADI2 axis. Cell Death Discov. 2022; 8(1): 20.

[34] Győrffy B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. Br J Pharmacol. 2024; 181(3): 362–374.

[35] Jin N, Matter WF, Michael LF, Qian Y, Gheyi T, Cano L, et al. The Angiopoietin-Like Protein 3 and 8 Complex Interacts with Lipoprotein Lipase and Induces LPL Cleavage. ACS Chem Biol. 2021; 16(3): 457–462.

[36] Dijk W, Ruppert PMM, Oost LJ, Kersten S. Angiopoietin-like 4 promotes the intracellular cleavage of lipoprotein lipase by PCSK3/furin in adipocytes. J Biol Chem. 2018; 293(36): 14134–14145.

[37] Karaman S, Detmar M. Mechanisms of lymphatic metastasis. J Clin Invest. 2014; 124(3): 922–928.

[38] Ramis JM, Bibiloni B, Moreiro J, García-Sanz JM, Salinas R, Proenza AM, et al. Tissue leptin and plasma insulin are associated with lipoprotein lipase activity in severely obese patients. J Nutr Biochem. 2005; 16(5): 279–285.

[39] Hopkins BD, Goncalves MD, Cantley LC. Obesity and Cancer Mechanisms: Cancer Metabolism. J Clin Oncol. 2016; 34(35): 4277–4283.

[40] Masuno H, Sakayama K, Okuda H. Effect of long-term treatment of 3T3-L1 adipocytes with chlorate on the synthesis, glycosylation, intracellular transport and secretion of lipoprotein lipase. Biochem J. 1998; 329(Pt 3): 461–468.

[41] de Candia P, Prattichizzo F, Garavelli S, Alviggi C, La Cava A, Matarese G. The pleiotropic roles of leptin in metabolism, immunity, and cancer. J Exp Med. 2021; 218(5): e20191593.

[42] Chen Y, Brandizzi F. IRE1: ER stress sensor and cell fate executor. Trends Cell Biol. 2013; 23(11): 547–555.

[43] Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2015; 43(Database issue): D512–D520.

[44] Yildirim Z, Baboo S, Hamid SM, Dogan AE, Tufanli O, Robichaud S, et al. Intercepting IRE1 kinase-FMRP signaling prevents atherosclerosis progression. EMBO Mol Med. 2022; 14(4): e15344.

[45] Korbecki J, Rębacz-Maron E, Kupnicka P, Chlubek D, Baranowska-Bosiacka I. Synthesis and Significance of Arachidonic Acid, a Substrate for Cyclooxygenases, Lipoxygenases, and Cytochrome P450 Pathways in the Tumorigenesis of Glioblastoma Multiforme, Including a Pan-Cancer Comparative Analysis. Cancers (Basel). 2023; 15(3): 946.

[46] Stack E, DuBois RN. Regulation of cyclo-oxygenase-2. Best Pract Res Clin Gastroenterol. 2001; 15(5): 787–800.

[47] Lala PK, Nandi P, Majumder M. Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer. Cancer Metastasis Rev. 2018; 37(2-3): 369–384.

[48] Butler LM, Perone Y, Dehairs J, Lupien LE, de Laat V, Talebi A, et al. Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020; 159: 245–293.

[49] Martínez-Garay C, Djouder N. Dietary interventions and precision nutrition in cancer therapy. Trends Mol Med. 2023; 29(7): 489–511.

[50] Hao X, Zhu X, Tian H, Lai G, Zhang W, Zhou H, et al. Pharmacological effect and mechanism of orlistat in anti-tumor therapy: A review. Medicine (Baltimore). 2023; 102(36): e34671.

[51] Zuo Y, He Z, Chen Y, Dai L. Dual role of ANGPTL4 in inflammation. Inflamm Res. 2023; 72(6): 1303–1313.

[52] Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018; 38(1): 27.

[53] Zhang R, Zhang K. A unified model for regulating lipoprotein lipase activity. Trends Endocrinol Metab. 2024; 23: S1043–2760(24)00045–6.

[54] Okochi-Takada E, Hattori N, Tsukamoto T, Miyamoto K, Ando T, Ito S, et al. ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis. Oncogene. 2014; 33(17): 2273–2278.

[55] Nakayama T, Hirakawa H, Shibata K, Abe K, Nagayasu T, Taguchi T. Expression of angiopoietin-like 4 in human gastric cancer: ANGPTL4 promotes venous invasion. Oncol Rep. 2010; 24(3): 599–606.

[56] Chen JW, Luo YJ, Yang ZF, Wen LQ, Huang L. Knockdown of angiopoietin-like 4 inhibits the development of human gastric cancer. Oncol Rep. 2018; 39(4): 1739–1746.

[57] Hübers C, Abdul Pari AA, Grieshober D, Petkov M, Schmidt A, Messmer T, et al. Primary tumor-derived systemic nANGPTL4 inhibits metastasis. J Exp Med. 2023; 220(1): e20202595.

[58] Huynh FK, Neumann UH, Wang Y, Rodrigues B, Kieffer TJ, Covey SD. A role for hepatic leptin signaling in lipid metabolism via altered very low density lipoprotein composition and liver lipase activity in mice. Hepatology. 2013; 57(2): 543–554.

[59] Maingrette F, Renier G. Leptin increases lipoprotein lipase secretion by macrophages: involvement of oxidative stress and protein kinase C. Diabetes. 2003; 52(8): 2121–2128.

[60] Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006; 55(1): 115–122.

RIGHTS & PERMISSIONS

2024 2024 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd on behalf of Sun Yat-sen University Cancer Center.